Clik here to view.
Santarus - Momentum
Shares of Santarus, Inc. ( SNTS ) have been on the upswing since the latter half of May 2012, driven by an earnings surprise of 150% in the first quarter of 2012. This specialty
View ArticleClik here to view.
FDA Approval for Santarus' Uceris - Analyst Blog
Santarus Inc. ( SNTS ) recently announced that the US Food and Drug Administration (FDA) has granted approval to Uceris (budesonide) for the induction of remission in patients suffering
View ArticleClik here to view.
Santarus Files Suit against Mylan - Analyst Blog
Santarus, Inc. ( SNTS ) recently filed a patent infringement lawsuit against Mylan, Inc. ( MYL ) which is looking to launch a generic version of Santarus' Fenoglide (fenofibrate - 40 mg
View ArticleClik here to view.
Santarus Launches Uceris in the US - Analyst Blog
Santarus, Inc ( SNTS ) recently announced the US launch of Uceris (budesonide) extended release tablets for the induction of remission in patients suffering from mild-to-moderate ulcerative
View ArticleClik here to view.
After-Hours Earnings Report for March 4, 2013 : ASNA, ABM, SHFL, SNTS, RSO,...
The following companies are expected to report earnings after hours on 03/04/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Ascena Retail Group, Inc. (
View ArticleClik here to view.
Mid-Day Market Update: Santarus Surges On Earnings Beat, Impax Tumbles
Midway through trading Tuesday, the Dow traded up 0.97 percent to 14,264.60 while the NASDAQ rose 1.25 percent to 3,221.85. The S&P also rose, gaining 0.98 percent to 1,540.09. Index
View ArticleClik here to view.
Santarus Tops, Focus on Zegerid - Analyst Blog
Santarus, Inc. ( SNTS ) reported fourth quarter 2012 earnings of 8 cents per share, well above the year-ago earnings of 3 cents per share and the Zacks Consensus Estimate of 1 cent per
View ArticleClik here to view.
Santarus' Uceris Data Published - Analyst Blog
Santarus, Inc ( SNTS ) recently announced that results from the CORE II clinical study were published in the journal Gut . The study, conducted in Europe, Australia, Israel and Russia, is
View ArticleClik here to view.
Santarus to Make Cash Milestone Payment - Analyst Blog
Santarus Inc. ( SNTS ) was recently notified that Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A., agreed to receive a commercial milestone payment of $7.0 million
View ArticleClik here to view.
Merck Likely to Beat 1Q Earnings - Analyst Blog
We expect Merck & Co. Inc. ( MRK ) to beat earnings expectations when it reports first-quarter 2013 results before the opening bell on May 1, 2013. Why a Likely Positive Surprise?
View ArticleClik here to view.
Wider-than-Expected Loss at Corcept - Analyst Blog
Corcept Therapeutics Inc. ( CORT ) posted a loss per share of 11 cents in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago quarter,
View ArticleClik here to view.
Market Wrap for Tuesday, May 7: S&P 500 Closes Up Again, First Solar Drops...
Toward the end of trading Tuesday, the Dow traded up 0.54 percent to 15,050.71 while the NASDAQ rose 0.07 percent to 3,395.07. The S&P rose, gaining 0.50 percent to 1,625.75. The Dow
View ArticleClik here to view.
Narrower-Than-Expected Loss at Rigel Pharma - Analyst Blog
Rigel Pharmaceuticals ' ( RIGL ) first-quarter 2013 loss of 29 cents per share was narrower than both the Zacks Consensus Estimate as well as the year-ago quarter loss of 32 cents. The
View ArticleClik here to view.
Positive Data on Celgene's Apremilast - Analyst Blog
Celgene Corporation ( CELG ) recently announced positive results from the PALACE 4 study on apremilast. The study is evaluating apremilast (20 mg and 30 mg), a novel, oral small-molecule
View ArticleClik here to view.
Pacira Reports Wider Loss - Analyst Blog
Pacira Pharmaceuticals, Inc. ( PCRX ) reported first quarter 2013 net loss per share of 60 cents, wider than the Zacks Consensus Estimate of a loss of 49 cents and the year-ago loss of 47
View ArticleClik here to view.
Simcere Beats 1Q Earnings & Revenue Estimate - Analyst Blog
Simcere Pharmaceutical Group ( SCR ) reported first quarter 2013 earnings of 9 cents per American Depositary Share (ADS) beating the Zacks Consensus Estimate by a penny. We note that each
View ArticleClik here to view.
Narrower-than-Expected Loss at MannKind - Analyst Blog
MannKind Corporation 's ( MNKD ) loss of 15 cents per share in the first quarter of 2013 was narrower than the Zacks Consensus Estimate of a loss of 16 cents and the year-ago loss of 27
View ArticleClik here to view.
Lilly Scraps Oncology Candidate - Analyst Blog
Eli Lilly and Company ( LLY ) recently announced a pipeline setback with its oncology candidate, enzastaurin, failing in a phase III study. Eli Lilly was evaluating enzastaurin as a
View ArticleClik here to view.
Pernix Reports Loss in 1Q - Analyst Blog
Pernix Therapeutics Holdings, Inc's ( PTX ) first quarter 2013 adjusted loss (including stock-based compensation expense) of 6 cents per share, compared unfavorably to the Zacks Consensus
View ArticleClik here to view.
Wider-Than-Expected Loss at Anacor - Analyst Blog
Anacor Pharmaceuticals, Inc. ( ANAC ) reported first quarter 2013 net loss per share of 42 cents, wider than the Zacks Consensus Estimate of a loss of 34 cents but narrower than the
View Article
